Therapeutic Solutions Intl Inc Stock Price, News & Analysis

Therapeutic Solutions International (TSOI) announced the issuance of United States Patent #11,504,410, covering a method to protect and regenerate neurological tissue using various nutraceuticals, including pterostilbene and Nigella sativa. This patent fortifies the company's position in the nutraceutical market and enhances the scientific backing of its product QuadraMune®. The company also noted independent confirmations of the effectiveness of QuadraMune® components, including a study by Johns Hopkins University demonstrating COVID-19 virus inhibition. This is TSOI's third patent linked to QuadraMune®, strengthening its innovation status.

Breathe Biologics, a subsidiary of TSOI, has announced promising data regarding a novel cellular therapy targeting Chronic Obstructive Pulmonary Disease (COPD). Research indicates that monocytic progenitors from umbilical cord blood can reduce inflammation and enhance lung function in animal models. The therapy’s efficacy was linked to the blockade of certain cytokines, suggesting a potential mechanism of action. Breathe Biologics plans to utilize JadiCells, currently in Phase III for COVID ARDS, for COPD treatment under IND# 28508. The collaboration highlights the innovation environment in the USA.

Therapeutic Solutions International (TSOI) has announced the launch of a spin-off company, Breathe Biologics, Inc., aimed at commercializing technologies for COPD. TSOI has licensed its assets, including an Investigational New Drug Application (IND) from the FDA, now known as “Allogeneic Umbilical Cord Mesenchymal Stem Cells, JadiCell.” This innovative stem cell therapy showcases potential in treating COPD and was highlighted by Dr. James Veltmeyer as having remarkable effects on inflammatory diseases. The company's president, Timothy Dixon, is optimistic about rapid commercialization and its positive impact on patients.

Therapeutic Solutions International (TSOI) announced a collaboration between its breast cancer spin-off, Res Nova Bio, and Veltmeyer MD Inc. to provide access to the anti-angiogenic immunotherapy ValloVax for patients with no treatment options. ValloVax has received FDA Investigational New Drug clearance and has demonstrated safety in various clinical applications. The therapy targets angiogenesis, a critical process in tumor growth, and has shown potential in clinical studies. TSOI is also advancing its Phase III trial in COVID-19 related conditions.

Therapeutic Solutions International (TSOI) has announced the formation of a spin-off company, Res Nova Bio, Inc., focusing on developing the StemVacs-V anti-angiogenesis immunotherapy for breast cancer. This innovative therapy utilizes induced pluripotent stem cells (iPSCs) to create a therapeutic vaccine that targets tumor blood vessels, promoting immune response. The technology is expected to enhance treatment efficacy, capitalizing on past successes with similar therapies. TSOI positions itself as a hub of innovation, aiming for accelerated development through this strategic spin-off.

Therapeutic Solutions International (TSOI) successfully administered JadiCells™ to a treatment-resistant epilepsy patient, resulting in remarkable recovery after 35 years of debilitating seizures. The treatment was conducted under the Right to Try Act based on preclinical data supporting JadiCells™ efficacy over standard therapies. The Company has filed a patent for JadiCells™ use in epilepsy and is advancing Phase III trials for COVID-19. TSOI has also treated patients with Chronic Traumatic Encephalopathy under FDA IND protocols.

Therapeutic Solutions International (TSOI) announced the receipt of a 'Notice of Allowance' for its patent on 'Neuroprotection and Neuroregeneration by Pterostilbene'. This patent offers protection for brain cell stimulation and repair using components of QuadraMune®, now in commercial use. The company has two prior patents covering QuadraMune® for immune modulation related to cancer and COVID-19. CMO Dr. James Veltmeyer emphasized its potential in addressing COVID-19 neurological effects. TSOI is currently conducting a Phase III trial in COVID-19.

Therapeutic Solutions International (TSOI) announced promising findings regarding its universal donor stem cell therapy, indicating potential applications for treating Chronic Obstructive Pulmonary Disease (COPD) and Acute Respiratory Distress Syndrome (ARDS). Research showed that CD103 expressing dendritic cells can transfer protection against these conditions to naïve mice. The company is advancing a Phase III clinical trial for JadiCells targeting ARDS from COVID-19 and is in discussions with the FDA regarding a new drug application for COPD treatment.

Therapeutic Solutions International (TSOI) has entered a $10 million Common Stock Purchase Agreement with GHS Investments, LLC. This agreement is structured as a non-toxic equity investment, providing funds to accelerate TSOI's Phase III clinical trial of JadiCells for COVID-19 related lung injury. The trial's success could lead to treatments for issues like 'long COVID.' TSOI holds 66 patents and has various INDs targeting conditions including Chronic Traumatic Encephalopathy and Acute Respiratory Distress Syndrome, demonstrating a robust focus on regenerative medicine and immunotherapy.